胸膜-话题@MedSci

#胸膜#

91篇内容 | 2856人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1666313, encodeId=6942166631333, content=<a href='/topic/show?id=bbaf8420118' target=_blank style='color:#2F92EE;'>#胸膜#</a>, objectTitle=CheckMate-743 III期研究结果：一线治疗不可切除的恶性胸膜间皮瘤，纳武利尤单抗联合伊匹木单抗显示出持久获益, objectType=article, longId=217090, objectId=179321e09027, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=179321e09027, replyNumber=0, likeNumber=0, createdTime=2021-12-16, rootId=0, userName=lifestar, userId=fbc026056217, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=179321e09027, moduleTitle=CheckMate-743 III期研究结果：一线治疗不可切除的恶性胸膜间皮瘤，纳武利尤单抗联合伊匹木单抗显示出持久获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=179321e09027)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666314, encodeId=2b4216663148b, content=<a href='/topic/show?id=bbaf8420118' target=_blank style='color:#2F92EE;'>#胸膜#</a>, objectTitle=国内“双免疫”疗法获批！伊匹木单抗联合纳武利尤单抗为恶性胸膜间皮瘤患者带来持久生存获益, objectType=article, longId=218467, objectId=821a21846eea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=821a21846eea, replyNumber=0, likeNumber=190, createdTime=2021-11-24, rootId=0, userName=lifestar, userId=fbc026056217, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=821a21846eea, moduleTitle=国内“双免疫”疗法获批！伊匹木单抗联合纳武利尤单抗为恶性胸膜间皮瘤患者带来持久生存获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=821a21846eea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666312, encodeId=600f166631276, content=<a href='/topic/show?id=bbaf8420118' target=_blank style='color:#2F92EE;'>#胸膜#</a>, objectTitle=Lancet Oncol：雷莫芦单抗+吉西他滨作为二线疗法可显著延长恶性胸膜间皮瘤患者的生存期！, objectType=article, longId=216812, objectId=832d216812a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=832d216812a4, replyNumber=0, likeNumber=83, createdTime=2022-08-20, rootId=0, userName=lifestar, userId=fbc026056217, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=832d216812a4, moduleTitle=Lancet Oncol：雷莫芦单抗+吉西他滨作为二线疗法可显著延长恶性胸膜间皮瘤患者的生存期！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=832d216812a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666309, encodeId=c846166630967, content=<a href='/topic/show?id=bbaf8420118' target=_blank style='color:#2F92EE;'>#胸膜#</a>, objectTitle=中国恶性胸膜间皮瘤临床诊疗指南（2021版），5分钟get要点！, objectType=article, longId=212767, objectId=e93d212e67f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e93d212e67f4, replyNumber=0, likeNumber=83, createdTime=2022-03-01, rootId=0, userName=lifestar, userId=fbc026056217, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e93d212e67f4, moduleTitle=中国恶性胸膜间皮瘤临床诊疗指南（2021版），5分钟get要点！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e93d212e67f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666308, encodeId=18b4166630824, content=<a href='/topic/show?id=bbaf8420118' target=_blank style='color:#2F92EE;'>#胸膜#</a>, objectTitle=里程碑！免疫“双子星”获国家药品监督管理局批准用于恶性胸膜间皮瘤一线治疗, objectType=article, longId=212620, objectId=76ec212620dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=76ec212620dd, replyNumber=0, likeNumber=70, createdTime=2021-06-17, rootId=0, userName=lifestar, userId=fbc026056217, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=76ec212620dd, moduleTitle=里程碑！免疫“双子星”获国家药品监督管理局批准用于恶性胸膜间皮瘤一线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=76ec212620dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666306, encodeId=272a1666306e3, content=<a href='/topic/show?id=bbaf8420118' target=_blank style='color:#2F92EE;'>#胸膜#</a>, objectTitle=Nat Commun：恶性胸膜间皮瘤的克隆结构可作为预后指标并影响肿瘤微环境, objectType=article, longId=208935, objectId=ef2720893512, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ef2720893512, replyNumber=0, likeNumber=70, createdTime=2021-07-14, rootId=0, userName=lifestar, userId=fbc026056217, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ef2720893512, moduleTitle=Nat Commun：恶性胸膜间皮瘤的克隆结构可作为预后指标并影响肿瘤微环境, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ef2720893512)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666304, encodeId=85091666304be, content=<a href='/topic/show?id=bbaf8420118' target=_blank style='color:#2F92EE;'>#胸膜#</a>, objectTitle=Lancet Oncol：以放疗后继胸膜外全肺切除术治疗恶性胸膜间皮瘤, objectType=article, longId=205843, objectId=21372058433a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=21372058433a, replyNumber=0, likeNumber=79, createdTime=2021-12-01, rootId=0, userName=lifestar, userId=fbc026056217, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=21372058433a, moduleTitle=Lancet Oncol：以放疗后继胸膜外全肺切除术治疗恶性胸膜间皮瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=21372058433a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666301, encodeId=8244166630123, content=<a href='/topic/show?id=bbaf8420118' target=_blank style='color:#2F92EE;'>#胸膜#</a>, objectTitle=FDA批准Opdivo联合Yervoy治疗恶性胸膜间皮瘤, objectType=article, longId=201577, objectId=bce42015e75f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bce42015e75f, replyNumber=0, likeNumber=0, createdTime=2020-11-29, rootId=0, userName=lifestar, userId=fbc026056217, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bce42015e75f, moduleTitle=FDA批准Opdivo联合Yervoy治疗恶性胸膜间皮瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bce42015e75f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666296, encodeId=b9a4166629612, content=<a href='/topic/show?id=bbaf8420118' target=_blank style='color:#2F92EE;'>#胸膜#</a>, objectTitle=Opdivo联合Yervoy显著延长胸膜间皮瘤患者存活率！, objectType=article, longId=199180, objectId=0851199180c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0851199180c7, replyNumber=0, likeNumber=96, createdTime=2020-10-16, rootId=0, userName=lifestar, userId=fbc026056217, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0851199180c7, moduleTitle=Opdivo联合Yervoy显著延长胸膜间皮瘤患者存活率！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0851199180c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666294, encodeId=99da16662946d, content=<a href='/topic/show?id=bbaf8420118' target=_blank style='color:#2F92EE;'>#胸膜#</a>, objectTitle=Clin Cancer Res：Ganetespib联合培美曲塞+铂类治疗恶性胸膜间皮瘤, objectType=article, longId=198667, objectId=2f6b19866e72, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f6b19866e72, replyNumber=0, likeNumber=98, createdTime=2020-12-09, rootId=0, userName=lifestar, userId=fbc026056217, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f6b19866e72, moduleTitle=Clin Cancer Res：Ganetespib联合培美曲塞+铂类治疗恶性胸膜间皮瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2f6b19866e72)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666298, encodeId=9d6c166629899, content=<a href='/topic/show?id=bbaf8420118' target=_blank style='color:#2F92EE;'>#胸膜#</a>, objectTitle=一文读懂小儿化脓性胸膜炎的诊断与治疗, objectType=article, longId=199867, objectId=850219986ecb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=850219986ecb, replyNumber=0, likeNumber=76, createdTime=2021-03-18, rootId=0, userName=lifestar, userId=fbc026056217, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=850219986ecb, moduleTitle=一文读懂小儿化脓性胸膜炎的诊断与治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=850219986ecb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666295, encodeId=0f7516662959e, content=<a href='/topic/show?id=bbaf8420118' target=_blank style='color:#2F92EE;'>#胸膜#</a>, objectTitle=CheckMate-743是且**证明一线免疫治疗能够改善恶性胸膜间皮瘤患者生存获益的III期临床试验, objectType=article, longId=199161, objectId=739d19916169, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=739d19916169, replyNumber=0, likeNumber=116, createdTime=2021-05-23, rootId=0, userName=lifestar, userId=fbc026056217, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=739d19916169, moduleTitle=CheckMate-743是且**证明一线免疫治疗能够改善恶性胸膜间皮瘤患者生存获益的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=739d19916169)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666305, encodeId=1e8416663059e, content=<a href='/topic/show?id=bbaf8420118' target=_blank style='color:#2F92EE;'>#胸膜#</a>, objectTitle=Eur Radiol:如何判断肺癌有没有侵犯脏层胸膜？, objectType=article, longId=208173, objectId=2c202081e38e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c202081e38e, replyNumber=0, likeNumber=82, createdTime=2021-11-11, rootId=0, userName=lifestar, userId=fbc026056217, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c202081e38e, moduleTitle=Eur Radiol:如何判断肺癌有没有侵犯脏层胸膜？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2c202081e38e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666292, encodeId=7d13166629215, content=<a href='/topic/show?id=bbaf8420118' target=_blank style='color:#2F92EE;'>#胸膜#</a>, objectTitle=CheckMate-743试验中期分析显示：纳武利尤单抗联合伊匹木单抗治疗恶性胸膜间皮瘤3期试验达主要终点, objectType=article, longId=192692, objectId=46461926922a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=46461926922a, replyNumber=0, likeNumber=173, createdTime=2020-05-06, rootId=0, userName=lifestar, userId=fbc026056217, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=46461926922a, moduleTitle=CheckMate-743试验中期分析显示：纳武利尤单抗联合伊匹木单抗治疗恶性胸膜间皮瘤3期试验达主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=46461926922a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666303, encodeId=88c21666303fb, content=<a href='/topic/show?id=bbaf8420118' target=_blank style='color:#2F92EE;'>#胸膜#</a>, objectTitle=美国FDA批准欧狄沃联合伊匹木单抗用于既往未经治疗的、不可切除的恶性胸膜间皮瘤患者，成为且目前**获批的免疫疗法, objectType=article, longId=201903, objectId=4d5c201903de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d5c201903de, replyNumber=0, likeNumber=79, createdTime=2021-05-10, rootId=0, userName=lifestar, userId=fbc026056217, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d5c201903de, moduleTitle=美国FDA批准欧狄沃联合伊匹木单抗用于既往未经治疗的、不可切除的恶性胸膜间皮瘤患者，成为且目前**获批的免疫疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4d5c201903de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666299, encodeId=02141666299a4, content=<a href='/topic/show?id=bbaf8420118' target=_blank style='color:#2F92EE;'>#胸膜#</a>, objectTitle=从入选主席研讨会到燃爆全球，听WCLC大会主席吴一龙教授谈胸膜间皮瘤治疗新突破, objectType=article, longId=200734, objectId=d5a1200e34de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d5a1200e34de, replyNumber=0, likeNumber=103, createdTime=2021-05-18, rootId=0, userName=lifestar, userId=fbc026056217, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d5a1200e34de, moduleTitle=从入选主席研讨会到燃爆全球，听WCLC大会主席吴一龙教授谈胸膜间皮瘤治疗新突破, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d5a1200e34de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666300, encodeId=6529166630040, content=<a href='/topic/show?id=bbaf8420118' target=_blank style='color:#2F92EE;'>#胸膜#</a>, objectTitle=Clin Cancer Res：Ganetespib联合铂类化疗治疗恶性胸膜间皮瘤, objectType=article, longId=200855, objectId=759d2008555c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=759d2008555c, replyNumber=0, likeNumber=0, createdTime=2021-08-05, rootId=0, userName=lifestar, userId=fbc026056217, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=759d2008555c, moduleTitle=Clin Cancer Res：Ganetespib联合铂类化疗治疗恶性胸膜间皮瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=759d2008555c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666302, encodeId=095216663026e, content=<a href='/topic/show?id=bbaf8420118' target=_blank style='color:#2F92EE;'>#胸膜#</a>, objectTitle=美国FDA批准欧狄沃®（纳武利尤单抗）联合伊匹木单抗成为且目前**获批的免疫疗法，用于既往未经治疗的、不可切除的恶性胸膜间皮瘤患者, objectType=article, longId=201898, objectId=555f2018985e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=555f2018985e, replyNumber=0, likeNumber=83, createdTime=2021-08-02, rootId=0, userName=lifestar, userId=fbc026056217, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=555f2018985e, moduleTitle=美国FDA批准欧狄沃®（纳武利尤单抗）联合伊匹木单抗成为且目前**获批的免疫疗法，用于既往未经治疗的、不可切除的恶性胸膜间皮瘤患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=555f2018985e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666284, encodeId=d7c9166628486, content=<a href='/topic/show?id=bbaf8420118' target=_blank style='color:#2F92EE;'>#胸膜#</a>, objectTitle=Eur Respir J：胸膜感染成年患者合并症和预后, objectType=article, longId=180602, objectId=77d718060244, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=77d718060244, replyNumber=0, likeNumber=77, createdTime=2020-03-08, rootId=0, userName=lifestar, userId=fbc026056217, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=77d718060244, moduleTitle=Eur Respir J：胸膜感染成年患者合并症和预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=77d718060244)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666297, encodeId=6d1d166629eb8, content=<a href='/topic/show?id=bbaf8420118' target=_blank style='color:#2F92EE;'>#胸膜#</a>, objectTitle=与化疗相比，纳武利尤单抗联合伊匹木单抗用于既往未经治疗的恶性胸膜间皮瘤患者显示出持久的生存获益, objectType=article, longId=199473, objectId=97211994e361, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=97211994e361, replyNumber=0, likeNumber=151, createdTime=2020-11-20, rootId=0, userName=lifestar, userId=fbc026056217, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=97211994e361, moduleTitle=与化疗相比，纳武利尤单抗联合伊匹木单抗用于既往未经治疗的恶性胸膜间皮瘤患者显示出持久的生存获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=97211994e361)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

胸膜

2020-05-29

lifestar (审核中...)

前往app查看评论内容

#胸膜#

CheckMate-743 III期研究结果：一线治疗不可切除的恶性胸膜间皮瘤，纳武利尤单抗联合伊匹木单抗显示出持久获益

2021-12-16

lifestar (审核中...)

前往app查看评论内容

#胸膜#

国内“双免疫”疗法获批！伊匹木单抗联合纳武利尤单抗为恶性胸膜间皮瘤患者带来持久生存获益

2021-11-24

lifestar (审核中...)

前往app查看评论内容

#胸膜#

Lancet Oncol：雷莫芦单抗+吉西他滨作为二线疗法可显著延长恶性胸膜间皮瘤患者的生存期！

2022-08-20

lifestar (审核中...)

前往app查看评论内容

#胸膜#

中国恶性胸膜间皮瘤临床诊疗指南（2021版），5分钟get要点！

2022-03-01

lifestar (审核中...)

前往app查看评论内容

#胸膜#

里程碑！免疫“双子星”获国家药品监督管理局批准用于恶性胸膜间皮瘤一线治疗

2021-06-17

lifestar (审核中...)

前往app查看评论内容

#胸膜#

Nat Commun：恶性胸膜间皮瘤的克隆结构可作为预后指标并影响肿瘤微环境

2021-07-14

lifestar (审核中...)

前往app查看评论内容

#胸膜#

Lancet Oncol：以放疗后继胸膜外全肺切除术治疗恶性胸膜间皮瘤

2021-12-01

lifestar (审核中...)

前往app查看评论内容

#胸膜#

FDA批准Opdivo联合Yervoy治疗恶性胸膜间皮瘤

2020-11-29

lifestar (审核中...)

前往app查看评论内容

#胸膜#

Opdivo联合Yervoy显著延长胸膜间皮瘤患者存活率！

2020-10-16

lifestar (审核中...)

前往app查看评论内容

#胸膜#

Clin Cancer Res：Ganetespib联合培美曲塞+铂类治疗恶性胸膜间皮瘤

2020-12-09

lifestar (审核中...)

前往app查看评论内容

#胸膜#

一文读懂小儿化脓性胸膜炎的诊断与治疗

2021-03-18

lifestar (审核中...)

前往app查看评论内容

#胸膜#

CheckMate-743是且**证明一线免疫治疗能够改善恶性胸膜间皮瘤患者生存获益的III期临床试验

2021-05-23

lifestar (审核中...)

前往app查看评论内容

#胸膜#

Eur Radiol:如何判断肺癌有没有侵犯脏层胸膜？

2021-11-11

lifestar (审核中...)

前往app查看评论内容

#胸膜#

CheckMate-743试验中期分析显示：纳武利尤单抗联合伊匹木单抗治疗恶性胸膜间皮瘤3期试验达主要终点

2020-05-06

lifestar (审核中...)

前往app查看评论内容

#胸膜#

美国FDA批准欧狄沃联合伊匹木单抗用于既往未经治疗的、不可切除的恶性胸膜间皮瘤患者，成为且目前**获批的免疫疗法

2021-05-10

lifestar (审核中...)

前往app查看评论内容

#胸膜#

从入选主席研讨会到燃爆全球，听WCLC大会主席吴一龙教授谈胸膜间皮瘤治疗新突破

2021-05-18

lifestar (审核中...)

前往app查看评论内容

#胸膜#

Clin Cancer Res：Ganetespib联合铂类化疗治疗恶性胸膜间皮瘤

2021-08-05

lifestar (审核中...)

前往app查看评论内容

#胸膜#

美国FDA批准欧狄沃®（纳武利尤单抗）联合伊匹木单抗成为且目前**获批的免疫疗法，用于既往未经治疗的、不可切除的恶性胸膜间皮瘤患者

2021-08-02

lifestar (审核中...)

前往app查看评论内容

#胸膜#

Eur Respir J：胸膜感染成年患者合并症和预后

2020-03-08

lifestar (审核中...)

前往app查看评论内容

#胸膜#

与化疗相比，纳武利尤单抗联合伊匹木单抗用于既往未经治疗的恶性胸膜间皮瘤患者显示出持久的生存获益

2020-11-20

科室
- - 订阅+
  - 更多科室
工具
服务